FANSIDAR Drug Patent Profile
✉ Email this page to a colleague
When do Fansidar patents expire, and what generic alternatives are available?
Fansidar is a drug marketed by Roche and is included in one NDA.
The generic ingredient in FANSIDAR is pyrimethamine; sulfadoxine. There are three drug master file entries for this compound. Additional details are available on the pyrimethamine; sulfadoxine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FANSIDAR?
- What are the global sales for FANSIDAR?
- What is Average Wholesale Price for FANSIDAR?
Summary for FANSIDAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 10 |
| Clinical Trials: | 32 |
| DailyMed Link: | FANSIDAR at DailyMed |
Recent Clinical Trials for FANSIDAR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Hospital Heidelberg | Phase 1/Phase 2 |
| KEMRI-Wellcome Trust Collaborative Research Program | Phase 1/Phase 2 |
| Sanaria Inc. | Phase 1/Phase 2 |
US Patents and Regulatory Information for FANSIDAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roche | FANSIDAR | pyrimethamine; sulfadoxine | TABLET;ORAL | 018557-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
